Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
11 evidence topics · 10 sources
NATIVE: histologic response in participants with type 2 diabetes
NATIVE: race of participants and applicability to other racial and ethnic groups
NATIVE: response by type 2 diabetes status and fibrosis stage F2 to F3 (company presentation)
NATIVE and other phase 2 studies: metabolic response by type 2 diabetes status (descriptive comparison)
NATIVE retrospective analysis: response by PNPLA3 I148M genotype
NATIVE post hoc analysis: response by weight change during treatment
NATIVE biomarker analysis: serum signatures of histologic response to lanifibranor
“Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings support utilizing a similar approach in a larger sample size (NATiV3, NCT03008070).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: resmetirom response in participants receiving background GLP-1 RA therapy
Comparator therapies: tirzepatide histologic response and metabolic change by type 2 diabetes status (SYNERGY-NASH post hoc analysis)
“Few MASH studies have compared histological responses in participants with T2D with those who do not have T2D.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In participants included in the present analyses, placebo-adjusted body weight reduction with tirzepatide 15 mg was nonsignificantly (P = 0.128 for interaction term) lower in participants with T2D (−14.5%) versus those without T2D (−22.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the association between fibrosis improvement response and changes in metabolic parameters such as HbA1c, body weight, and adiponectin were driven mainly by significant associations in the T2D group and were not observed in the non-T2D group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator therapies: dapagliflozin response by age and sex (DEAN)
“Thirdly, a high proportion of male and relatively younger participants were recruited in this trial because they may be more willing to accept liver biopsy at screening. Although the results showed no age and sex differences of dapagliflozin on MASH improvement, female and the older patients were underrepresented in the current study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote